Addison Advisors LLC Purchases 731 Shares of Bristol-Myers Squibb (NYSE:BMY)

Addison Advisors LLC lifted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 23.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 3,851 shares of the biopharmaceutical company’s stock after buying an additional 731 shares during the quarter. Addison Advisors LLC’s holdings in Bristol-Myers Squibb were worth $198,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in BMY. Gilliland Jeter Wealth Management LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $274,000. Fulton Breakefield Broenniman LLC grew its position in Bristol-Myers Squibb by 4.6% in the 4th quarter. Fulton Breakefield Broenniman LLC now owns 4,744 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 209 shares during the period. Headlands Technologies LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter worth approximately $650,000. Citizens Financial Group Inc. RI grew its position in Bristol-Myers Squibb by 6.3% in the 4th quarter. Citizens Financial Group Inc. RI now owns 27,693 shares of the biopharmaceutical company’s stock worth $1,421,000 after purchasing an additional 1,646 shares during the period. Finally, Kovack Advisors Inc. grew its position in Bristol-Myers Squibb by 29.7% in the 4th quarter. Kovack Advisors Inc. now owns 23,025 shares of the biopharmaceutical company’s stock worth $1,181,000 after purchasing an additional 5,279 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

Shares of BMY traded up $0.15 during midday trading on Friday, hitting $44.85. 21,281,927 shares of the company traded hands, compared to its average volume of 12,141,314. The firm has a 50 day moving average of $51.03 and a 200-day moving average of $51.18. Bristol-Myers Squibb has a 52 week low of $44.34 and a 52 week high of $69.10. The stock has a market cap of $90.90 billion, a price-to-earnings ratio of -14.47, a PEG ratio of 16.25 and a beta of 0.39. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 50.04%. The business had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same quarter in the prior year, the firm earned $2.05 EPS. The business’s revenue was up 4.7% on a year-over-year basis. On average, analysts forecast that Bristol-Myers Squibb will post 0.55 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.35%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is -77.42%.

Analyst Ratings Changes

BMY has been the subject of a number of research analyst reports. Bank of America downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the stock from $68.00 to $60.00 in a research report on Wednesday, January 3rd. Redburn Atlantic cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. BMO Capital Markets dropped their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research note on Friday. Barclays dropped their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday. Finally, StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $60.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.